Beam Therapeutics (BEAM) Total Non-Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Total Non-Current Liabilities for 8 consecutive years, with $310.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 7.86% year-over-year to $310.9 million; the TTM figure through Mar 2026 stood at $310.9 million (down 7.86% YoY), while the FY2025 annual figure was $242.6 million, down 34.27% from the prior year.
• Total Non-Current Liabilities rose to $310.9 million in Q1 2026 per BEAM's latest filing, from $242.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $635.5 million in Q3 2022 and bottomed at $242.6 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $454.0 million across 5 years, with a median of $443.4 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 127.57% — and 2025, when it sank 34.27%.
• Beam Therapeutics' Total Non-Current Liabilities stood at $606.9 million in 2022, then decreased by 21.62% to $475.7 million in 2023, then retreated by 22.39% to $369.1 million in 2024, then tumbled by 34.27% to $242.6 million in 2025, then increased by 28.13% to $310.9 million in 2026.
• Business Quant data shows BEAM's Total Non-Current Liabilities at $310.9 million in Q1 2026, $242.6 million in Q4 2025, and $344.8 million in Q3 2025.